Ligand Pharmaceuticals Inc. Announces Positive Preclinical Data for Glucagon Program in Model of Type 1 Diabetes

Published: Jun 24, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced the presentation of a poster titled “Glucagon Receptor Antagonist LGD-6972 Is Efficacious in Streptozotocin-Induced Diabetic Mice” at the 73rd Scientific Sessions of the American Diabetes Association in Chicago. The poster provides data from preclinical studies of Ligand’s novel compound, LGD-6972, demonstrating significant glucose lowering activity in an animal model of type 1 diabetes.

Help employers find you! Check out all the jobs and post your resume.

Back to news